These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9765752)

  • 1. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer.
    Earle CC; Evans WK
    Cancer Prev Control; 1997 Oct; 1(4):282-8. PubMed ID: 9765752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
    Earle CC; Evans WK
    Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.
    Socinski MA
    Oncologist; 1999; 4(5):408-16. PubMed ID: 10551557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
    Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
    J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacoeconomics of cancer therapies.
    Bishop JF; Macarounas-Kirchman K
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
    Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
    Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
    Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
    J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
    Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
    Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule.
    Ranson MR; Jayson G; Perkins S; Anderson H; Thatcher N
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-6-S12-9. PubMed ID: 9331111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
    Ceresoli GL; Gregorc V; Cordio S; Bencardino KB; Schipani S; Cozzarini C; Bordonaro R; Villa E
    Lung Cancer; 2004 May; 44(2):231-9. PubMed ID: 15084388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
    Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial.
    Stathopoulos GP; Katis C; Tsavdaridis D; Dimitroulis J; Karaindros D; Stathopoulos J; Dimou E
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):555-60. PubMed ID: 16520987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
    Leighl NB; Paz-Ares L; Douillard JY; Peschel C; Arnold A; Depierre A; Santoro A; Betticher DC; Gatzemeier U; Jassem J; Crawford J; Tu D; Bezjak A; Humphrey JS; Voi M; Galbraith S; Hann K; Seymour L; Shepherd FA
    J Clin Oncol; 2005 Apr; 23(12):2831-9. PubMed ID: 15837997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent paclitaxel and radiation for non-small cell lung cancer.
    Akerley W; Choy H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):85-9. PubMed ID: 10210545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
    Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.
    Fidias P; Supko JG; Martins R; Boral A; Carey R; Grossbard M; Shapiro G; Ostler P; Lucca J; Johnson BE; Skarin A; Lynch TJ
    Clin Cancer Res; 2001 Dec; 7(12):3942-9. PubMed ID: 11751486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.